Janssen Receives EC’s Approval for its Ebola Vaccine Dual Regimen
Janssen’s Darzalex (daratumumab) Combination Regimen Receives CHMP’s Positive Opinion for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
Shots:
- The vaccines composing the two-dose regimen, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) receives EC’s approval under exceptional circumstances, following accelerated assessment of the MAAs and CHMP’s positive opinion
- The regimen includes Ad26.ZEBOV as the first dose, based on Janssen’s AdVac viral vector technology, and MVA-BN-Filo as the second dose, based on Bavarian Nordic’s MVA-BN technology, administered ~8wks. later
- Janssen’s vaccine regimen is indicated for active immunization to prevent Ebola virus disease caused by the Zaire ebolavirus species in individuals aged ≥1yrs.
Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter